Date: December 9, 2020
IMV is a clinical stage biopharmaceutical company. They are focused on making immunotherapy more effective, more broadly applicable, as well as more widely available to people facing cancer and other serious diseases.
"We are initially targeting two cancers, ovarian cancer and lymphoma, where there is a high medical need," says CEO, Frederic Ors.
IMV’s proprietary technology is the DPX platform. It's a unique way of helping the human immune system put up a better fight against cancer cells and viruses. This patented technology leverages a novel mechanism of action that enables the activation of immune cells in vivo, which are aimed at generating powerful new synthetic therapeutic capabilities.
IMV’s lead candidate is DPX-Survivac. It is a T cell-activating immunotherapy that combines the utility of the platform with a novel cancer target: survivin. IMV is currently assessing DPX-Survivac in advanced ovarian cancer, as well as a combination therapy in multiple clinical studies with Merck. IMV is also developing a DPX-based vaccine to fight against COVID-19.
"In biotech, you don't often have the opportunity to participate in something that's not just an incremental improvement of something, but that has the potential to become a new class," says Ors.
It's very easy to produce and deliver the drug to patients. In fact, cancer patients just have to receive a simple injection every two months. Further, it doesn’t require hospitalization and you can receive it at the clinic or even home with a nurse. Another advantage is that the product itself is freeze-dried. This means it can be stored at room temperature or normal fridge temperature for a very long period of time.
For more information on IMV Inc. (TSX: IMV, Nasdaq: IMV) please fill out the form below.